CI

At a glance

ClinicalIndex Comparison Record
Phase 4Not Yet Recruiting· 232 target
Drug / intervention
Huaier granuledrug
Likely dose
Huaier granule 10gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05871437
NCT05871437Phase 4Not Yet Recruiting
CompareCT.gov

Prospective, Multicenter, Randomized Controlled Clinical Trial on the Effect of Huaier Granules in Reducing Tumor Marker Levels in Patients With Early-Stage Breast Cancer

Fudan University·interventional·Posted May 23, 2023·Updated Sep 8, 2025

In Brief

A Phase 4 clinical trial evaluating Huaier granule for Breast Cancer. Not yet recruiting, targeting 232 participants across 1 site.

Detailed Summary

This study is a prospective, multicenter, randomized controlled clinical trial designed to evaluate the rate of reduction of tumor markers to normal levels in breast cancer patients treated with Huaier granules compared to the control group.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
CollaboratorsLinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology

Timeline

Phase 4Not Yet Recruiting
20242025202620272028
First PostedMay 23, 2023
Enrollment StartSep 1, 2025
Primary CompletionJan 1, 2026
Study CompletionJan 1, 2028
TodayJul 1, 2026
Enrollment to primary: 4 monthsPosted 3.1 years ago

Interventions

Huaier granuledrug

On the basis of routine clinical treatment/follow-up, take Huaier Granules orally, 10g each time, three times a day, for one year continuously or until disease progression, intolerable toxicity, withdrawal from the study for any reason or death occurs, whichever occurs first.